SecurityHLIX / Helix TCS, Inc.
Common Shares Outstanding70,569,647 shares (as of 2018-06-30)
Total Insiders14
Total Directors5
Total Officers2

Stock Insider Trading (from SEC Form 4)

Helix TCS, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

HLIX / Helix TCS, Inc. insiders include HELIX OPPORTUNITIES LLC, RSG5, LLC, Schweibold Andrew, Ferraro Terence J, RSF5, LLC, and Rose Management Group LLC Rose Capital Fund I GP, LLC, McMahon Daniel J, VENEGAS ZACHARY L, RSF4, LLC, Nightstone Unlimited, Inc., Ogur Scott Matthew, Vo Patrick, Rosenthal Jonathan, .

Insider Roster

Insider Dir Off 10% Shares Owned
Ogur Scott Matthew Chief Financial Officer, Director, 10% Owner
X X X 22,605,483
VENEGAS ZACHARY L CEO, Director, 10% Owner
X X X 22,605,483
HELIX OPPORTUNITIES LLC 10% Owner
X 22,605,483
Ferraro Terence J Director, 10% Owner
Nightstone Unlimited, Inc. 10% Owner
X X 9,238,882
Rose Capital Fund I GP, LLC 10% Owner
Schweibold Andrew Director, 10% Owner
RSF4, LLC 10% Owner
Rosenthal Jonathan 10% Owner
X 2,488,888
Vo Patrick Director
X 1,395,785
McMahon Daniel J Director
X 26,954

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-09-11 4 HELIX OPPORTUNITIES LLC S X D 1.0500 -6,319 22,605,483 23,735,757
2018-09-11 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.0500 -6,319 22,605,483 23,735,757
2018-09-11 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.0500 -6,319 22,605,483 23,735,757
2018-09-06 4 HELIX OPPORTUNITIES LLC S X D 1.1500 -6,134 22,611,802 26,003,572
2018-09-06 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.1500 -6,134 22,611,802 26,003,572
2018-09-06 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.1500 -6,134 22,611,802 26,003,572
2018-08-30 4 HELIX OPPORTUNITIES LLC S X D 1.2000 -10,000 22,617,936 27,141,523
2018-08-30 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2000 -10,000 22,617,936 27,141,523
2018-08-30 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2000 -10,000 22,617,936 27,141,523
2018-08-28 4 HELIX OPPORTUNITIES LLC S X D 1.2600 -5,452 22,627,936 28,511,199
2018-08-28 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2600 -5,452 22,627,936 28,511,199
2018-08-28 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2600 -5,452 22,627,936 28,511,199
2018-07-26 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.1800 -240 22,633,388 26,707,398
2018-07-25 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2600 -1,280 22,633,628 28,518,371
2018-07-26 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.1800 -3,252 22,633,388 26,707,398
2018-07-25 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2600 -1,240 22,633,628 28,518,371
2018-07-26 4 HELIX OPPORTUNITIES LLC S X D 1.1800 -240 22,633,388 26,707,398
2018-07-25 4 HELIX OPPORTUNITIES LLC S X D 1.2600 -1,280 22,633,628 28,518,371
2018-07-24 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2800 -3,252 22,634,908 28,972,682
2018-07-23 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2500 -1,240 22,638,160 28,297,700
2018-07-24 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2800 -3,252 22,634,908 28,972,682
2018-07-23 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2500 -1,240 22,638,160 28,297,700
2018-07-23 4 HELIX OPPORTUNITIES LLC S X D 1.2500 -1,240 22,638,160 28,297,700
2018-07-16 4 HELIX OPPORTUNITIES LLC S X D 1.2800 -3,252 22,634,908 28,972,682
2018-07-16 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2200 -529 22,639,400 27,620,068
2018-07-13 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2700 -2,430 22,639,929 28,752,710
2018-07-16 4 HELIX OPPORTUNITIES LLC S X D 1.2200 -529 22,639,400 27,620,068
2018-07-13 4 HELIX OPPORTUNITIES LLC S X D 1.2700 -2,430 22,639,929 28,752,710
2018-07-16 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2200 -529 22,639,400 27,620,068
2018-07-13 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.2700 -2,430 22,639,929 28,752,710
2018-07-12 4 HELIX OPPORTUNITIES LLC S X D 1.3100 -4,757 22,642,359 29,661,490
2018-07-11 4 HELIX OPPORTUNITIES LLC S X D 1.3400 -1,392 22,647,116 30,347,135
2018-07-12 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3100 -4,757 22,642,359 29,661,490
2018-07-11 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3400 -1,392 22,647,116 30,347,135
2018-07-12 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3100 -4,757 22,642,359 29,661,490
2018-07-11 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3400 -1,392 22,647,116 30,347,135
2018-07-10 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3700 -5,675 22,648,508 31,028,456
2018-07-09 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3700 -1,402 22,654,183 31,036,231
2018-07-10 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3700 -5,675 22,648,508 31,028,456
2018-07-09 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.3700 -1,402 22,654,183 31,036,231
2018-07-10 4 HELIX OPPORTUNITIES LLC S X D 1.3700 -5,675 22,648,508 31,028,456
2018-07-09 4 HELIX OPPORTUNITIES LLC S X D 1.3700 -1,402 22,654,183 31,036,231
2018-07-06 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.4900 -1,467 22,655,585 33,756,822
2018-07-05 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.4500 -1,410 22,657,052 32,852,725
2018-07-06 4 HELIX OPPORTUNITIES LLC S X D 1.4900 -1,467 22,655,585 33,756,822
2018-07-05 4 HELIX OPPORTUNITIES LLC S X D 1.4500 -1,410 22,657,052 32,852,725
2018-07-06 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.4900 -1,467 22,655,585 33,756,822
2018-07-05 4 VENEGAS ZACHARY L As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.4500 -1,410 22,657,052 32,852,725
2018-07-03 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.5000 -603 22,658,462 33,987,693
2018-07-03 4 Ogur Scott Matthew As Controlling Manager and Member of Helix Opportunities, LLC S X I 1.5000 -603 22,658,462 33,987,693
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

BRIEF-Helix TCS, Inc. Announces Record Revenues For 2017

2018-04-02 reuters
* HELIX TCS, INC. ANNOUNCES RECORD REVENUES FOR 2017 Source text for Eikon: Further company coverage: (1-0)